Seven Fleet Capital Management LP Grows Stake in Compass Pathways PLC Sponsored ADR $CMPS

Seven Fleet Capital Management LP increased its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 295.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 158,021 shares of the company’s stock after acquiring an additional 118,021 shares during the period. Seven Fleet Capital Management LP’s holdings in Compass Pathways were worth $874,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CMPS. Corient Private Wealth LLC increased its position in Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after acquiring an additional 1,200 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the last quarter. Conservest Capital Advisors Inc. grew its stake in shares of Compass Pathways by 24.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares during the period. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways during the 4th quarter valued at about $38,000. Finally, Raymond James Financial Inc. increased its position in shares of Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after purchasing an additional 6,228 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Trading Down 1.9%

CMPS stock opened at $11.35 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. Compass Pathways PLC Sponsored ADR has a 1-year low of $3.92 and a 1-year high of $15.40. The business has a 50 day simple moving average of $12.53 and a two-hundred day simple moving average of $9.15. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -3.60 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current fiscal year.

Analyst Ratings Changes

CMPS has been the topic of several recent research reports. Compass Point set a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, July 7th. Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Maxim Group upped their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a report on Friday, May 15th. UBS Group set a $18.00 price target on shares of Compass Pathways in a research note on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.